Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II crossover study of inhaled bimosiamose in moderate to severe COPD
2009-017257-35Phase 2Completed
- Sponsor
- Revotar Biopharmaceuticals
- Start
- Dec 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of bimosiamose in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Revotar Biopharmaceuticals. Primary endpoints: Absolute neutrophil cell count in induced sputum and Interleukin-8 in induced sputum. Started Dec 2009; status: completed.
02
Drugs
bimosiamose
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2009-017257-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017257-35.